Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13170000 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2POLBTDP1LMNAALDH1A1 | |
| SCHEMBL1198071 | 0.84 | LMNA (0.58) | SMN1; SMN2POLBTDP1LMNAALDH1A1 | |
| SCHEMBL6188814 | 0.82 | MAPT (0.52) | SMN1; SMN2POLBTDP1LMNAALDH1A1 | |
| SCHEMBL23138505 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2POLBTDP1LMNAALDH1A1 | |
| SCHEMBL18718147 | 0.79 | SMN1; SMN2 (0.47) | SMN1; SMN2POLBTDP1LMNAALDH1A1 | |
| SCHEMBL1279630 | 0.78 | SMN1; SMN2 (0.42) | SMN1; SMN2POLBTDP1LMNAALDH1A1 | |
| SCHEMBL18718164 | 0.78 | SMN1; SMN2 (0.49) | SMN1; SMN2POLBTDP1LMNAALDH1A1 | |
| SCHEMBL1198660 | 0.77 | NPC1 (0.42) | POLBLMNAALDH1A1KDM4EPKM | |
| SCHEMBL2355085 | 0.77 | SMN1; SMN2 (0.45) | SMN1; SMN2POLBTDP1LMNAALDH1A1 | |
| SCHEMBL23138330 | 0.77 | SMN1; SMN2 (0.45) | SMN1; SMN2POLBTDP1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461348-B2 | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| US-8461348-B2 | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-03 | — | — | US | disclosed |
| EP-2264017-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | PDE3B, PDE5A, PDE2A | SMN1; SMN2 2057/4885POLB 4137/4885TDP1 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.